当前位置: 首页 > 期刊 > 《上海医药》 > 2018年第1期
编号:13203977
PCI术后双联抗血小板治疗致皮肤瘀斑患者的药学监护(4)
http://www.100md.com 2018年1月5日 上海医药 2018年第1期
     [10] Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium [J]. Circulation, 2011, 123(23): 2736-2747.

    [11] Kikkert WJ, van Geloven N, van der Laan MH, et al. The prognostic value of bleeding academic research consortioum(BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI(Thrombolysis In Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications [J]. J Am Coll Cardiol, 2014, 63(18): 1866-1875.

    [12] 中国医师协会心血管内科医师分会, 中国医师协会心血管内科医师分会血栓防治专业委员会, 中华医学会消化内镜学分会, 等. 急性冠状动脉综合征抗栓治疗合并出血防治多学科专家共识[J]. 中华内科杂志, 2016, 55(10): 813-824.

    [13] Halvorsen S, Storey RF, Rocca B, et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis [J]. Eur Heart J, 2017, 38(19):1455-1462.

    [14] 赵发兵, 陈泽奎. PCI患者双抗血小板治疗1年后变单抗治疗的可行性分析[J]. 西南国防医藥, 2017, 27(2): 169-172., http://www.100md.com(周琰 李静)
上一页1 2 3 4